Abstract: The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.

Abstract: Disclosed is a pyridazinone compound represented by Formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, stereoisomer, or isotopic variant thereof. The compound can be used for preparation of medicinal products for treatment and/or prophylaxis of a disease or condition associated with thyroid hormone abnormalities. The compound has higher selectivity to TH?, better pharmacokinetic parameters, desired stability, and higher agonistic activity toward TH?.

Abstract: Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain CDK2/4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders.

Abstract: Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Abstract: Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Abstract: Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bc1-2 inhibitors can be used to treat cell proliferative disorders.

Abstract: The present invention relates to a measuring and compensating method for channel mismatch of an ultra-high speed time-wavelength interleaved optical pulse sequence, by employing a generating module of the to-be tested ultra-high speed time-wavelength interleaved optical pulse sequence, an optical spectrum measuring module, an electrical frequency measuring module, and a data analyzing and processing module. The present invention obtains mismatch information of the pulse sequence for each channel by means of measurement and analysis of the ultra-high speed time-wavelength interleaved optical pulse sequence, thus overcoming the bottleneck of inadequate sampling of time-domain observation via an oscilloscope. The channel mismatch information obtained by the present invention may act as a basis for channel mismatch compensation and correction for the ultra-high speed time-wavelength interleaved optical pulse sequence.

Abstract: Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to a measuring and compensating method for channel mismatch of an ultra-high speed time-wavelength interleaved optical pulse sequence, by employing a generating module of the to-be tested ultra-high speed time-wavelength interleaved optical pulse sequence, an optical spectrum measuring module, an electrical frequency measuring module, and a data analyzing and processing module. The present invention obtains mismatch information of the pulse sequence for each channel by means of measurement and analysis of the ultra-high speed time-wavelength interleaved optical pulse sequence, thus overcoming the bottleneck of inadequate sampling of time-domain observation via an oscilloscope. The channel mismatch information obtained by the present invention may act as a basis for channel mismatch compensation and correction for the ultra-high speed time-wavelength interleaved optical pulse sequence.